Amneal Receives U. S. FDA Approval for Brekiya® - GlobeNewswire DHE can be used at any point during a migraine attack, and may protect patients from headache recurrence 1, 3,4 Approximately 39 million Americans are living with migraine 7, and up to one
FDA Approves Brekiya (dihydroergotamine mesylate) Injection . . . BRIDGEWATER, N J , May 15, 2025 -- Amneal Pharmaceuticals, Inc (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that the U S Food and Drug Administration (FDA) has approved Brekiya (dihydroergotamine mesylate) injection, the first and only dihydroergotamine (DHE) autoinjector for the acute treatment of migraine with or
Amneal Pharmaceuticals, Inc. - Amneal Receives U. S. FDA . . . Brekiya ® becomes the first and only DHE autoinjector that allows patients to self-administer the same medication used in hospitals in a ready-to-use form Product will be available for appropriate patients in the second half of 2025 BRIDGEWATER, N J , May 15, 2025 (GLOBE NEWSWIRE) - Amneal Pharmaceuticals, Inc (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that the U S
FDA Approves Brekiya, First and Only DHE Autoinjector, for . . . Migraines affect 39 million Americans, and cluster headaches impact up to 1 million, highlighting the need for effective treatment options The autoinjector is beneficial for patients unresponsive to oral therapies due to efficacy issues, nausea, or delayed dosing
New Treatments for Migraines: What Actually Works in 2025? After two months of preventive use, patients experienced a reduction of 4 migraine days per month, with over 50% reporting at least a 50% reduction in moderate to severe headache days [23] Recently, Nerivio became the first non-pharmacological migraine treatment to receive commercial insurance coverage in the United States [24]